MISSION

Innovation, excellence, integrity, and safety define our values.

Our mission, “Therapy for Life,” is centred on a novel biotechnological enzyme designed to counteract the core pathological processes of arteriosclerosis. Developed through extensive research and protected by a robust patent portfolio, this therapeutic agent targets a major unmet need.

Arteriosclerosis continues to impose a significant health burden worldwide, with no current treatment capable of reversing vascular damage.

We offer strategic investors access to a scalable, protected, and highly relevant solution in the field of cardiovascular biotechnology.

THE PROBLEM

Familial Hypercholesterolaemia (FH), characterised by abnormal lipid accumulation and accelerated arteriosclerosis, is a key pathological driver of cardiovascular morbidity and mortality. Arterial narrowing due to plaque formation leads to serious complications such as myocardial infarction, heart failure, and cerebral ischaemia.

Despite established lipid-lowering treatments, options to reverse structural vascular damage remain limited.

Pharmact has been dedicated to addressing this issue since 2014.

THE SOLUTION

We have developed a first-in-class biotherapeutic enzyme that addresses the core mechanisms behind Familial Hypercholesterolaemia and arteriosclerosis. Preclinical results confirm a strong effect in reducing arterial plaque. The therapy is fully protected by international patents, ensuring long-term value creation.

Despite limited early-stage material, initial results demonstrate compelling therapeutic impact. The platform represents a scalable, high-impact innovation with clear relevance to healthcare systems and global markets.

Development Highlights:

• Proof-of-concept and pre-toxicology completed

• Study framework approved by BfArM / EMA

• Patent portfolio established

Upcoming Milestones:

• GMP production launch (May 2025)

• Toxicology studies (October 2025)

• EMA application for clinical trial entry